The original success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies heavily reliant on off-patent versions presents a complex picture. Although early earnings were impressive, the end of patents and the rise of cheaper alternatives have eroded sales. Thus, a thorough assessment of present financial perfor